Medtronic traded at $101.07 this Wednesday February 11th, decreasing $0.30 or 0.30 percent since the previous trading session. Looking back, over the last four weeks, Medtronic lost 4.28 percent. Over the last 12 months, its price rose by 10.64 percent. Looking ahead, we forecast Medtronic to be priced at 99.86 by the end of this quarter and at 91.20 in one year, according to Trading Economics global macro models projections and analysts expectations.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.